Evaluating the efficacy and safety of SHR-1701 combined with chemotherapy for the perioperative treatment of locally advanced resectable Siewert type II adenocarcinoma of the esophagogastric junction.
HB≥90g/L；
ANC≥1.5×109/L；
PLT≥100×109/L；
ALT and AST<2.5ULN（liver metastasis: ALT and AST<5ULN）；
Known signs of active bleeding from the lesion (except for a positive fecal occult blood test);
Diagnosis of HER2-positive adenocarcinoma of the stomach or gastroesophageal junction;
Cardia or pyloric obstruction;
Currently participating in an interventional clinical trial, or having received treatment with another investigational drug or device within 4 weeks prior to the first dose;